Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 7/20 | 0.41 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.41 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.38 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.38 |
| ▸ | CPN1 | P15169 | 1/20 | 0.37 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.37 |
| ▸ | QDPR | P09417 | 1/20 | 0.37 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.36 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11990125 | 0.89 | PIK3CD (0.42) | DPP4DPP7PIK3CDEPHX2EPHX1 | |
| SCHEMBL20372808 | 0.86 | ALDH1A1 (0.39) | DPP4DPP7PIK3CDEPHX2EPHX1 | |
| SCHEMBL13742489 | 0.83 | DPP4 (0.41) | DPP4DPP7EPHX2DPP8DPP9 | |
| SCHEMBL22622606 | 0.80 | PIK3CD (0.43) | DPP4DPP7PIK3CDEPHX2EPHX1 | |
| SCHEMBL24040182 | 0.79 | GNAI3 (0.43) | — | |
| SCHEMBL21024634 | 0.78 | GNAI3 (0.42) | — | |
| SCHEMBL21983443 | 0.78 | MEN1 (0.38) | DPP4MAPT | |
| SCHEMBL24345186 | 0.77 | GNAI3 (0.41) | EPHX2 | |
| SCHEMBL22803237 | 0.76 | — | — | |
| SCHEMBL7883168 | 0.76 | PIK3CD (0.46) | DPP4DPP7PIK3CDEPHX2EPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10208023-B2 | Heterocyclic inhibitors of the sodium channel | DeGiacomo, Mark G. (US) | 2019-02-19 | — | — | US | disclosed |
| US-10172858-B2 | Combination pharmaceutical compositions and uses thereof | INTELLIKINE LLC (US) | 2019-01-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10208023-B2 | Heterocyclic inhibitors of the sodium channel | SCN1B, TRPV1, SCN1A | DPP4 4515/4885DPP7 4321/4885PIK3CD 3686/4885 |
| US-10172858-B2 | Combination pharmaceutical compositions and uses thereof | CDC25C, CCNC, CDC25B | DPP4 3649/4885DPP7 2992/4885PIK3CD 446/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.